Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Lets Promote Make In...

    Lets Promote Make In India: Orthopaedic Manufacturers Knock on PMs door for level playing field

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-09-13T17:19:08+05:30  |  Updated On 13 Sept 2018 5:19 PM IST
    Lets Promote Make In India: Orthopaedic Manufacturers Knock on PMs door for level playing field
    Government is planning to tap the trade margin at 65% In case of the orthopaedic Implant. This means that the difference in price between the first point of sale, i.e the price at which the manufacturer sells to the distributor and the MRP cannot be more than 65%.

    New Delhi: In the light of the recent faulty hip implant case, Orthopaedic Implant Manufacturers Association(OIMA) an association of 65 companies indigenously manufacturing orthopaedic devices has now written to the Prime Minister asking for a level playing field.

    "The recent issue of faulty hip implants supplied by a multinational, Johnson & Johnson, has confirmed that despite giving all sops to multinationals, sometimes even at the cost of indigenous manufacturers, it is not a guarantee that a product of multinationals would be of great quality." the association wrote in the letter.

    The association consists of 65 member companies that manufacture screw and plates, Total Hip Replacement, Total Knee Replacement, Spine implant, Arthroscopy Implants, External Fixator which treats patients of Trauma, bone degeneration.

    Orthopaedic Implant Manufacturers Association(OIMA) knocked the door of PM on the dispute of orthopaedics implant capping up to 65%, which considers the first point of sale as a manufacturer in case of domestic implants and distributors in case of imported products. This, the association pointed out was causing them a huge disadvantage and demanded a level playing field to compete with foreign manufacturers.

    The National Pharmaceutical Pricing (NPP) Authority announced price caps on orthopaedic implants used in knee replacement surgeries, bringing the price of the basic model of implants down by 65% in August 2017.

    Government is planning to tap the trade margin at 65% In case of the orthopaedic Implant. This means that the difference in price between the first point of sale, i.e the price at which the manufacturer sells to the distributor and the MRP cannot be more than 65%.

    “For the Indian manufacturers, the first point of sale is the manufacturer, whereas, for foreign multinationals or importers of foreign implants, the first point of sale is the first distributor in India, and hence for them the first sale price is not the price at which they import the implant, but their selling price to the first distributor after adding their cost, without any cap, claimed on education, awareness and R&D,” the letter added

    Asking for a level playing field, the association drew the attention to the following demands

    • Tender qualification for all Indian drug licence holders for tenders floated by local, state and central government to ensure fair competition and fair price amongst all, whether they be the smallest entrepreneur or the biggest. Presently, many govt. institutions impose unreasonable conditions that have no bearing on product quality in order to have a very high level of turnover, which leads to monopolization by one or two companies.

    • In continuation with the Hon'ble Prime Minister's "Ease of Doing Business", the association requested the PM to have a regular dialogue between all regulatory authorities and OIMA as a major stakeholder for smooth implementation of rules and regulations for orthopaedic implants as a medical device. tors and hospitals, unlike other 22 nos. of medical devices.


    "We feel that Indian brands do not have to be dependent immediately on the international market for raw material, tests, etc. We need to develop such facilities in India itself to stop the outflow of our foreign exchange reserves and avoid the shortage of such implants during unusual and adverse conditions of even trade war or war with such countries." the letter added







    Ayushmann Bharatcapping 65%Ease of Doing BusinessExternal FixatorFaulty implanthip implantimplantJ&JJohnson & JohnsonNational Pharmaceutical PricingNPPOIMAOrthopaedic Implant Manufacturers AssociationSpine implantSwachh Bharat AbhiyaanTotal Hip ReplacementTotal Knee Replacement

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok